On 7th April 2020, Can- Fite BioPharma Ltd announced that its product CF102 had met its efficacy endpoints in a Phase II exploratory study for non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) and it also demonstrated good safety. This Phase II double-blind, placebo-controlled, dose-finding efficacy and safety study included 60 NAFLD patients with or without NASH at three clinical sites in Israel, including Hadassah Medical Center in Jerusalem, Israel Rabin Medical Center, Holy Family Hospital in Nazareth. The primary endpoint of this study was dose-dependent and significant, and experiments showed that CF102 had a good therapeutic effect and was a persistent and potent candidate for clinical treatment of NAFLD/NASH.
NAFLD is the most common chronic liver disease worldwide, and the spectrum of NAFLD disease includes non-alcoholic hepatic steatosis, NASH, etc. The prevalence of NAFLD in ordinary adults ranges from 6.3% to 45%, with 10% to 30% of cases being NASH. The prevalence of NAFLD in most Asian countries including China is at the middle-to-upper level (> 25%), which has overtaken developed countries such as Europe and the United States, which has become a new challenge in the field of liver disease and metabolism in China. Hence, NAFLD poses a serious threat to national health and social development in China. CMS Group believes that once CF102 has been proven in rigorous clinical trials, a new treatment option will be offered to patients.
CMS has acquired product rights in Greater China for products CF101 and CF102 from Can- Fite through its wholly owned affiliate in August 2018.